Shire plc News

The report covers the companys structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360A view of the company.

's stock had its "conviction buy" rating restated by equities researchers at Goldman Sachs in a report issued on Friday.

Bruhn comes on board at a time when Promedior is rapidly advancing its product candidates in human clinical trials for diseases involving fibrosis, including idiopathic pulmonary fibrosis, myelofibrosis and retinal diseases.

LEXINGTON, Mass., May 14, 2012 /PRNewswire/ -- Shire plc , the global specialty biopharmaceutical company, today announced its support of the first global hereditary angioedema awareness day, being held on May 16th, with a new Facebook page "Shire Supports HAE Awareness Day." Developed to help raise awareness of HAE, for every person who likes the ... (more)

Other equities research analysts have also recently issued reports about the stock.

Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing.

Shire plc , the global specialty biopharmaceutical company, today announced that it will present scientific data from one oral and 16 poster presentations at the American Psychiatric Association 165th Annual Meeting to be held .

First quarter 2012 revenues were comprised of revenues from the Company's new collaboration and license agreement with Shire AG to develop ZFP TherapeuticsA for hemophilia and other monogenic diseases, existing collaboration agreements with Dow AgroSciences and Sigma-Aldrich Corporation, enabling technology agreements and research grants.

MagForce AG / MagForce AG hires Christian von Volkmann as Head of Finance . Processed and transmitted by Thomson Reuters ONE.

Good afternoon and welcome to the Sangamo BioSciences teleconference to discuss first quarter 2012 financial results.

Protalix BioTherapeutics Inc. soared in Tel Aviv trading after the biopharmaceutical company's first product won approval from the U.S. Food and Drug Administration.